Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A.
BACKGROUND
Incobotulinum is a newly developed botulinum toxin A in which the complexing proteins had been removed.


OBJECTIVE
The aim was to compare the efficacy and safety of incobotulinum with onabotulinum in treating periocular rhytides and masseteric hypertrophy.


METHODS
A randomized, double-blind, split-face study was planned. Fifty-six patients were treated for periocular rhytides and the other 56 patients were treated for masseteric hypertrophy. Onabotulinum was injected on one side of the face and incobotulinum was injected on the other side of the face. The degree of periocular rhytides and masseteric hypertrophy was rated using Fitzpatrick Wrinkle Classification System (FWCS) and 10-point visual analogue scale (VAS) (0: the minimum to 10: the maximum). Objective and subjective rating was performed at pretreatment and every posttreatment follow-up visit by investigators and subjects.


RESULTS
The efficacy and safety of incobotulinum were not inferior to those of onabotulinum in treating periocular rhytides and masseteric hypertrophy up to 16 weeks after injection. There were no noteworthy differences in the onset time of effect between two botulinum toxins for periocular wrinkles and masseteric hypertrophy. No adverse event was reported.


CONCLUSIONS
Incobotulinum provided non-inferior efficacy and safety for the treatment of periocular rhytides and masseteric hypertrophy compared with classic onabotulinum.
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea.
Jae Hyung
JH
Lee
Ji Ho
JH
Park
Soo Keun
SK
Lee
Kwang Ho
KH
Han
Sang Duck
SD
Kim
Chun Sik
CS
Yoon
Jae Young
JY
Park
Joo Heung
JH
Lee
Jun Mo
JM
Yang
Jong Hee
JH
Lee
D000293:Adolescent; D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D004311:Double-Blind Method; D005123:Eye; D005145:Face; D005152:Facial Muscles / Q000187:drug effects; D005260:Female; D006801:Humans; D006984:Hypertrophy; D007273:Injections, Intramuscular; D008297:Male; D008406:Masseter Muscle / Q000187:drug effects* / Q000473:pathology; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome; D055815:Young Adult
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA